Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (Registrant) covers the month of July 2011. The document serves as a Substantial Shareholder Notice under Section 671B of the Corporations Act 2001 (Australia), reporting a change in the voting power of a substantial holder due to dilution.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document is strictly a regulatory notice regarding shareholding structure.
Material Changes Versus Prior Period
The substantial holder, Baywick Pty Ltd, experienced a reduction in voting power from 7.29% to 6.20% as of June 30, 2011. The number of votes held by Baywick Pty Ltd remained constant at 17,055,000. The decrease in percentage ownership was caused by the dilution of shareholding due to the issue of new Prana Biotechnology Limited (PBT) shares, rather than a sale of existing holdings.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a statutory disclosure of ownership changes.
Important Facts for Investor Verification
- Substantial Holder: Baywick Pty Ltd (ACN 007 226 708).
- Voting Power Change: Decreased from 7.29% to 6.20%.
- Reason for Change: Dilution resulting from the issuance of new PBT shares; no shares were sold by the holder.
- Share Count: Baywick Pty Ltd holds 17,055,000 ordinary shares (unchanged from previous notice).
- Composition of Interest: The 17,055,000 votes are comprised of direct holdings by Baywick Pty Ltd (13,965,000), NRB Developments (2,970,000), Crystal Triangle (90,000), and G. Kempler (30,000).